checkAd

     569  0 Kommentare Novavax RSV F Vaccine Clinical Trial Data in Women of Child Bearing Age Published in the Journal of Infectious Disease - Seite 3 

    Contact:

Novavax, Inc.

Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer

Andrea N. Flynn, Ph.D.
Senior Manager, Investor Relations

ir@novavax.com  
240-268-2000
               
Russo Partners, LLC
         
David Schull
Todd Davenport, Ph.D.

david.schull@russopartnersllc.com 
todd.davenport@russopartnersllc.com
212-845-4271
     
     


    This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
    The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
    Source: Novavax, Inc. via Globenewswire

    Lesen Sie auch

    HUG#1951219
    Seite 3 von 3



    Diskutieren Sie über die enthaltenen Werte



    GlobeNewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Verfasst von GlobeNewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Novavax RSV F Vaccine Clinical Trial Data in Women of Child Bearing Age Published in the Journal of Infectious Disease - Seite 3 Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that the full data set from its clinical trial of the RSV …